235 related articles for article (PubMed ID: 12756509)
21. MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
Nachtigal P; Pospisilova N; Pospechova K; Jamborova G; Kopecky M; Jaynes R; Briestensky J; Santar I; Smahelova A; Solichova D; Zdansky P; Semecky V
Life Sci; 2006 Mar; 78(17):1983-9. PubMed ID: 16305803
[TBL] [Abstract][Full Text] [Related]
22. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients.
Nomura S; Shouzu A; Omoto S; Inami N; Shimazu T; Satoh D; Kajiura T; Yamada K; Urase F; Maeda Y; Iwasaka T
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):440-7. PubMed ID: 19525846
[TBL] [Abstract][Full Text] [Related]
23. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
[TBL] [Abstract][Full Text] [Related]
24. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
Bilz S; Wagner S; Schmitz M; Bedynek A; Keller U; Demant T
J Lipid Res; 2004 Jan; 45(1):174-85. PubMed ID: 14523053
[TBL] [Abstract][Full Text] [Related]
25. [The effect of atorvastatin on the expression of CD55, CD59 in patients with hyperlipidemia].
Liu YM; He JC; Yang JG; Liu YY; Yan X; Zhao L; Ma XW; Shang DY; Qiao CD; Li WX; Wang JY
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Dec; 33(12):1075-9. PubMed ID: 16563273
[TBL] [Abstract][Full Text] [Related]
26. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia.
Takebayashi K; Matsumoto S; Wakabayashi S; Inukai Y; Matsutomo R; Aso Y; Inukai T
Metabolism; 2005 Sep; 54(9):1225-9. PubMed ID: 16125534
[TBL] [Abstract][Full Text] [Related]
27. Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study.
Ghayour-Mobarhan M; Lamb DJ; Vaidya N; Livingstone C; Wang T; Ferns GA
Angiology; 2005; 56(1):61-8. PubMed ID: 15678257
[TBL] [Abstract][Full Text] [Related]
28. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
Giral P; Bruckert E; Jacob N; Chapman MJ; Foglietti MJ; Turpin G
Atherosclerosis; 2001 Feb; 154(2):421-7. PubMed ID: 11166775
[TBL] [Abstract][Full Text] [Related]
29. [Atorvastatin inhibits scavenger receptor A and monocyte chemoattractant protein-1 expressions in foam cell].
Zhu GY; Zhu XL; Li RT; Liu TB; Shang DY; Zhang Y
Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jul; 35(7):666-9. PubMed ID: 17961438
[TBL] [Abstract][Full Text] [Related]
30. Hemostatic effects of atorvastatin versus simvastatin.
Kadikoylu G; Yukselen V; Yavasoglu I; Bolaman Z
Ann Pharmacother; 2003 Apr; 37(4):478-84. PubMed ID: 12659599
[TBL] [Abstract][Full Text] [Related]
31. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
32. Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances.
Krysiak R; Stachura-Kułach A; Okopień B
Pharmacol Rep; 2010; 62(1):120-30. PubMed ID: 20360622
[TBL] [Abstract][Full Text] [Related]
33. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
Krysiak R; Gdula-Dymek A; Okopien B
Am J Cardiol; 2011 Apr; 107(7):1010-1018.e1. PubMed ID: 21276586
[TBL] [Abstract][Full Text] [Related]
34. Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients.
Kario K; Matsuo T; Hoshide S; Kobayashi H; Sakata T; Mizuno O; Mitsuhashi T; Ikeda U; Miyata T; Shimada K
Blood Coagul Fibrinolysis; 1999 Jul; 10(5):269-76. PubMed ID: 10456618
[TBL] [Abstract][Full Text] [Related]
35. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
Okopień B; Krysiak R; Herman ZS
J Clin Endocrinol Metab; 2006 May; 91(5):1770-8. PubMed ID: 16492702
[TBL] [Abstract][Full Text] [Related]
36. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
37. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Choi IS; Shin EK
J Am Coll Cardiol; 2005 May; 45(10):1649-53. PubMed ID: 15893182
[TBL] [Abstract][Full Text] [Related]
38. Influence of HMG-CoA-reductase inhibitors on the body fat status.
Bucek RA; Reiter M; Wirth S; Pourazim A; Minar E
Vasa; 2006 May; 35(2):92-5. PubMed ID: 16796007
[TBL] [Abstract][Full Text] [Related]
39. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients.
Rezaie-Majd A; Maca T; Bucek RA; Valent P; Müller MR; Husslein P; Kashanipour A; Minar E; Baghestanian M
Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1194-9. PubMed ID: 12117737
[TBL] [Abstract][Full Text] [Related]
40. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.
Pasceri V; Cheng JS; Willerson JT; Yeh ET
Circulation; 2001 May; 103(21):2531-4. PubMed ID: 11382718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
